Effects of omapatrilat on cardiac nerve sprouting and structural remodeling in experimental congestive heart failure

Yong-Mei Cha, Margaret May Redfield, Sonia Shah, Win Kuang Shen, Michael C. Fishbein, Peng Sheng Chen

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: Congestive heart failure (CHF) results in decreased cardiac sympathetic innervation. Objectives: The purpose of this study was to test the hypothesis that therapy with the vasopeptidase inhibitor omapatrilat (OMA) attenuates cardiac neuronal remodeling in CHF. Methods: We induced CHF in dogs with rapid ventricular pacing for 5 weeks with (CHF + OMA group, n = 8) or without (CHF group, n = 10) concomitant OMA treatment (10 mg/kg twice daily). Cardiac catheterization and echocardiography were performed to determine cardiac structure and hemodynamic parameters. Myocardial nerve density was determined by immunocytochemical staining with anti-growth associated protein 43 (GAP43) and anti-tyrosine hydroxylase (TH) antibodies. Seven normal dogs were used as histologic controls. Results: In the CHF group, ascites developed in 3 dogs and 4 dogs died, compared with no ascites or death in the CHF + & OMA group (P = .07). In the 6 CHF dogs that survived, all had atrial fibrosis, severely depressed left ventricular systolic function, and increased atrial and ventricular chamber size. OMA treatment decreased the atrial and ventricular chamber sizes and the degree of atrial fibrosis. Most CHF dogs showed severe myocardial denervation, although some showed normal or abnormally high nerve counts. OMA treatment prevented heterogeneous reduction of nerve density. The left ventricular TH-positive nerve densities were 128 ± 170 μm2/mm2, 261 ± 185 μm2/mm2, and 503 ± 328 μm2/mm2 (P < .05), and the atrial GAP43-positive nerve densities were 1,683 ± 1,365 μm2/mm2, 305 ± 368 μm2/ mm2, and 1,278 ± 1,479 μm2/mm2 (P < .05) for the control, CHF, and CHF + OMA groups, respectively. Conclusion: CHF results in heterogeneous cardiac denervation. Long-term OMA treatment prevented the reduction of nerve density and promoted beneficial cardiac structural remodeling.

Original languageEnglish (US)
Pages (from-to)984-990
Number of pages7
JournalHeart Rhythm
Volume2
Issue number9
DOIs
StatePublished - Sep 2005

Fingerprint

Heart Failure
Dogs
GAP-43 Protein
Tyrosine 3-Monooxygenase
Denervation
Ascites
omapatrilat
Fibrosis
Therapeutics
Neuronal Plasticity
Cardiac Catheterization
Left Ventricular Function
Echocardiography
Hemodynamics
Staining and Labeling
Antibodies

Keywords

  • Heart failure
  • Innervation
  • Remodeling

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effects of omapatrilat on cardiac nerve sprouting and structural remodeling in experimental congestive heart failure. / Cha, Yong-Mei; Redfield, Margaret May; Shah, Sonia; Shen, Win Kuang; Fishbein, Michael C.; Chen, Peng Sheng.

In: Heart Rhythm, Vol. 2, No. 9, 09.2005, p. 984-990.

Research output: Contribution to journalArticle

Cha, Yong-Mei ; Redfield, Margaret May ; Shah, Sonia ; Shen, Win Kuang ; Fishbein, Michael C. ; Chen, Peng Sheng. / Effects of omapatrilat on cardiac nerve sprouting and structural remodeling in experimental congestive heart failure. In: Heart Rhythm. 2005 ; Vol. 2, No. 9. pp. 984-990.
@article{8e9a455427c94314807342e71bc2f2ec,
title = "Effects of omapatrilat on cardiac nerve sprouting and structural remodeling in experimental congestive heart failure",
abstract = "Background: Congestive heart failure (CHF) results in decreased cardiac sympathetic innervation. Objectives: The purpose of this study was to test the hypothesis that therapy with the vasopeptidase inhibitor omapatrilat (OMA) attenuates cardiac neuronal remodeling in CHF. Methods: We induced CHF in dogs with rapid ventricular pacing for 5 weeks with (CHF + OMA group, n = 8) or without (CHF group, n = 10) concomitant OMA treatment (10 mg/kg twice daily). Cardiac catheterization and echocardiography were performed to determine cardiac structure and hemodynamic parameters. Myocardial nerve density was determined by immunocytochemical staining with anti-growth associated protein 43 (GAP43) and anti-tyrosine hydroxylase (TH) antibodies. Seven normal dogs were used as histologic controls. Results: In the CHF group, ascites developed in 3 dogs and 4 dogs died, compared with no ascites or death in the CHF + & OMA group (P = .07). In the 6 CHF dogs that survived, all had atrial fibrosis, severely depressed left ventricular systolic function, and increased atrial and ventricular chamber size. OMA treatment decreased the atrial and ventricular chamber sizes and the degree of atrial fibrosis. Most CHF dogs showed severe myocardial denervation, although some showed normal or abnormally high nerve counts. OMA treatment prevented heterogeneous reduction of nerve density. The left ventricular TH-positive nerve densities were 128 ± 170 μm2/mm2, 261 ± 185 μm2/mm2, and 503 ± 328 μm2/mm2 (P < .05), and the atrial GAP43-positive nerve densities were 1,683 ± 1,365 μm2/mm2, 305 ± 368 μm2/ mm2, and 1,278 ± 1,479 μm2/mm2 (P < .05) for the control, CHF, and CHF + OMA groups, respectively. Conclusion: CHF results in heterogeneous cardiac denervation. Long-term OMA treatment prevented the reduction of nerve density and promoted beneficial cardiac structural remodeling.",
keywords = "Heart failure, Innervation, Remodeling",
author = "Yong-Mei Cha and Redfield, {Margaret May} and Sonia Shah and Shen, {Win Kuang} and Fishbein, {Michael C.} and Chen, {Peng Sheng}",
year = "2005",
month = "9",
doi = "10.1016/j.hrthm.2005.05.016",
language = "English (US)",
volume = "2",
pages = "984--990",
journal = "Heart Rhythm",
issn = "1547-5271",
publisher = "Elsevier",
number = "9",

}

TY - JOUR

T1 - Effects of omapatrilat on cardiac nerve sprouting and structural remodeling in experimental congestive heart failure

AU - Cha, Yong-Mei

AU - Redfield, Margaret May

AU - Shah, Sonia

AU - Shen, Win Kuang

AU - Fishbein, Michael C.

AU - Chen, Peng Sheng

PY - 2005/9

Y1 - 2005/9

N2 - Background: Congestive heart failure (CHF) results in decreased cardiac sympathetic innervation. Objectives: The purpose of this study was to test the hypothesis that therapy with the vasopeptidase inhibitor omapatrilat (OMA) attenuates cardiac neuronal remodeling in CHF. Methods: We induced CHF in dogs with rapid ventricular pacing for 5 weeks with (CHF + OMA group, n = 8) or without (CHF group, n = 10) concomitant OMA treatment (10 mg/kg twice daily). Cardiac catheterization and echocardiography were performed to determine cardiac structure and hemodynamic parameters. Myocardial nerve density was determined by immunocytochemical staining with anti-growth associated protein 43 (GAP43) and anti-tyrosine hydroxylase (TH) antibodies. Seven normal dogs were used as histologic controls. Results: In the CHF group, ascites developed in 3 dogs and 4 dogs died, compared with no ascites or death in the CHF + & OMA group (P = .07). In the 6 CHF dogs that survived, all had atrial fibrosis, severely depressed left ventricular systolic function, and increased atrial and ventricular chamber size. OMA treatment decreased the atrial and ventricular chamber sizes and the degree of atrial fibrosis. Most CHF dogs showed severe myocardial denervation, although some showed normal or abnormally high nerve counts. OMA treatment prevented heterogeneous reduction of nerve density. The left ventricular TH-positive nerve densities were 128 ± 170 μm2/mm2, 261 ± 185 μm2/mm2, and 503 ± 328 μm2/mm2 (P < .05), and the atrial GAP43-positive nerve densities were 1,683 ± 1,365 μm2/mm2, 305 ± 368 μm2/ mm2, and 1,278 ± 1,479 μm2/mm2 (P < .05) for the control, CHF, and CHF + OMA groups, respectively. Conclusion: CHF results in heterogeneous cardiac denervation. Long-term OMA treatment prevented the reduction of nerve density and promoted beneficial cardiac structural remodeling.

AB - Background: Congestive heart failure (CHF) results in decreased cardiac sympathetic innervation. Objectives: The purpose of this study was to test the hypothesis that therapy with the vasopeptidase inhibitor omapatrilat (OMA) attenuates cardiac neuronal remodeling in CHF. Methods: We induced CHF in dogs with rapid ventricular pacing for 5 weeks with (CHF + OMA group, n = 8) or without (CHF group, n = 10) concomitant OMA treatment (10 mg/kg twice daily). Cardiac catheterization and echocardiography were performed to determine cardiac structure and hemodynamic parameters. Myocardial nerve density was determined by immunocytochemical staining with anti-growth associated protein 43 (GAP43) and anti-tyrosine hydroxylase (TH) antibodies. Seven normal dogs were used as histologic controls. Results: In the CHF group, ascites developed in 3 dogs and 4 dogs died, compared with no ascites or death in the CHF + & OMA group (P = .07). In the 6 CHF dogs that survived, all had atrial fibrosis, severely depressed left ventricular systolic function, and increased atrial and ventricular chamber size. OMA treatment decreased the atrial and ventricular chamber sizes and the degree of atrial fibrosis. Most CHF dogs showed severe myocardial denervation, although some showed normal or abnormally high nerve counts. OMA treatment prevented heterogeneous reduction of nerve density. The left ventricular TH-positive nerve densities were 128 ± 170 μm2/mm2, 261 ± 185 μm2/mm2, and 503 ± 328 μm2/mm2 (P < .05), and the atrial GAP43-positive nerve densities were 1,683 ± 1,365 μm2/mm2, 305 ± 368 μm2/ mm2, and 1,278 ± 1,479 μm2/mm2 (P < .05) for the control, CHF, and CHF + OMA groups, respectively. Conclusion: CHF results in heterogeneous cardiac denervation. Long-term OMA treatment prevented the reduction of nerve density and promoted beneficial cardiac structural remodeling.

KW - Heart failure

KW - Innervation

KW - Remodeling

UR - http://www.scopus.com/inward/record.url?scp=25444527550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25444527550&partnerID=8YFLogxK

U2 - 10.1016/j.hrthm.2005.05.016

DO - 10.1016/j.hrthm.2005.05.016

M3 - Article

C2 - 16171755

AN - SCOPUS:25444527550

VL - 2

SP - 984

EP - 990

JO - Heart Rhythm

JF - Heart Rhythm

SN - 1547-5271

IS - 9

ER -